Revolution Medicines Executives Execute Large Stock Sale and Prepare for Potential Additional Sales: A Warning Signal for Investors

Executive Leadership Realizes Over $9 Million Gains on January 7

Revolution Medicines, Inc. (RVMD) executives executed concentrated stock‐option exercises and share sales on January 7, 2026, netting more than $9 million in profits in a single day. According to multiple Form 4 filings submitted to the SEC on January 9, both the Chief Operating Officer and Chief Financial Officer followed pre-arranged Rule 10b5-1 trading plans to exercise options and dispose of shares at prevailing market prices. Such sizable insider transactions may influence short-term share volatility and investor sentiment.

## COO Exercises $7.5 Million in Options, Sells $9.54 Million in Shares; Retains Significant Stake

Form 4 data show COO Margaret A. Horn exercised two tranches of stock options on January 7, acquiring 75,000 shares at strike prices of $42.45 (51,406 shares, ~$2.18 million) and $29.80 (23,594 shares, ~$0.70 million). She then sold the bulk of these shares in three blocks:

• 53,096 shares at $100.02 (≈$5.31 million)
• 20,204 shares at $101.79 (≈$2.06 million)
• 1,700 shares at $102.90 (≈$0.17 million)

Total gross proceeds reached approximately $9.54 million. After these transactions, Horn directly holds 141,053 shares (including 61,226 RSUs), valued at about $14.3 million based on a $101 per-share reference price.

CFO Executes 10b5-1 Plan, Sells 10,000 Shares; Maintains Over 100,000 Shares

On the same day, CFO Jack Anders exercised 10,000 options at $42.45 (≈$0.42 million) and immediately sold 10,000 shares at $98.00, realizing roughly $0.98 million in proceeds. This activity was part of a Rule 10b5-1 trading plan adopted on December 16, 2024. Pre-tax intrinsic gain on the transaction is estimated at $0.56 million. Post-sale, Anders holds 108,065 shares—indicating continued alignment with long-term company performance.

## Form 144 Filing Signals Potential Additional Sales

Also on January 7, a Form 144 was filed to notify the proposed sale of Revolution Medicines securities by an insider or affiliate. While the filing omits specific share quantities and seller identity, its timing alongside large insider sales suggests possible future supply pressure. Investors should note that Form 144 serves as a sale intention notice; actual execution and timing depend on market conditions.

Investor Takeaway: Profit-Taking vs. Long-Term Confidence

These filings indicate key executives realized substantial gains amid a recent share-price rally, signaling short-term profit-taking. Notably, all transactions were conducted under pre-established 10b5-1 plans, and both officers retain significant equity stakes worth tens of millions of dollars. With no adverse developments in business fundamentals (e.g., earnings, financing needs, regulatory issues), long-term investors may find some reassurance. However, RVMD’s share price volatility may intensify as pipeline progress, clinical data readouts, capital-raising initiatives, insider sales and potential Form 144 executions interplay. Investors should closely monitor insider transaction trends and any repetition of such trades.